+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast

Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast

Current Medicinal Chemistry 16(11): 1400-1417

Idiopathic Pulmonary Fibrosis (IPF) is characterized by injury and loss of lung epithelial cells, accumulation of fibroblasts/myofibroblasts and abnormal remodeling of the lung parenchyma. The prognosis for IPF patients is poor and current therapies are largely ineffective in preventing respiratory failure. Current therapeutic approaches target epithelial cell replacement, manipulation of fibroblasts/myofibroblasts, modulation of procoagulant/fibrinolytic activities, cytokine and growth factor production, angiogenesis, and reduction of oxidative stress. Myofibroblasts are the primary effector cells in fibrosis. These cells may be derived by the activation and proliferation of resident lung fibroblasts, from epithelial-mesenchymal transition (EMT), or through recruitment of circulating fibrocytes. Transforming growth factor beta (TGFbeta) is a profibrotic factor that increases fibroblast proliferation, stimulates the synthesis and deposition of connective tissue, and inhibits connective tissue breakdown. TGFbeta acts through the promoter of the type 1 collagen gene causing increased collagen synthesis. In addition, TGFbeta induces EMT in alveolar epithelial cells (AECs) in vitro and in vivo. AECs exhibit substantial plasticity and may serve as a source of fibroblasts and/or myofibroblasts in lung fibrosis. Therapeutic interventions interfering with the pathways that lead to myofibroblast expansion and AEC apoptosis should be of considerable benefit in the treatment of IPF. This review will focus on the critical role of TGFbeta on AECs EMT and myofibroblasts in the development of fibrosis.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 055398183

Download citation: RISBibTeXText

PMID: 19355895

Related references

Recent Advances in Molecular Targets and Treatment of Idiopathic Pulmonary Fibrosis: Focus on Tgf Signaling and the Myofibroblast. Current Medicinal Chemistry 16(11): 1400-1417, 2009

Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132(4): 1311-1321, 2007

Recent advances in pathogenesis and molecular targeted therapies of idiopathic pulmonary fibrosis.. Zhonghua Jie He He Hu Xi Za Zhi 32(12): 945-947, 2016

Recent advances in idiopathic pulmonary fibrosis. Tuberculosis and Respiratory Diseases 74(1): 1-6, 2013

Recent advances in idiopathic pulmonary fibrosis. Chest 132(2): 637-650, 2007

Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets. Cns and Neurological Disorders Drug Targets 9(3): 335-348, 2010

Recent advances in managing idiopathic pulmonary fibrosis. F1000research 6: 2052, 2017

Recent advances in understanding idiopathic pulmonary fibrosis. F1000research 5, 2016

TGFbeta induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGFbeta, PDGF and integrin signaling. Experimental Eye Research 75(6): 645-657, 2002

Idiopathic pulmonary fibrosis: recent diagnostic and therapeutic advances. Revue Medicale Suisse 10(451): 2208-10, 2212-3, 2015

Recent advances in the study of prognosis of idiopathic pulmonary fibrosis. Zhonghua Jie He He Hu Xi Za Zhi 34(2): 139-142, 2012

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. Pharmacology and Therapeutics 152: 18-27, 2016

Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. Journal of Medicinal Chemistry 60(2): 527-553, 2017

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. International Journal of Molecular Sciences 20(3), 2019

Recent advances on the role of chemokines/chemokine receptors in the pathogenesis of idiopathic pulmonary fibrosis. Recenti Progressi in Medicina 98(2): 90-96, 2007